About AbbVie
AbbVies mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on peoples lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, womens health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Since 2013, AbbVie has expanded its commitment to the San Francisco Bay Area, now represented by three facilities in Redwood City, South San Francisco, Sunnyvale and a future new Bay Area headquarters in South San Francisco. AbbVie employees in the Bay Area drive AbbVies research-based, innovation driven missions in healthcare. Specifically, Bay Area employees bring deep scientific expertise and commercial excellence to advance cancer care. Current oncology areas of focus include immuno-oncology, tumor targeting, tumor dependency and precision medicine. With facilities positioned in the heart of the biotechnology industry, we are able to collaborate with the best and brightest minds in oncology.
We are seeking a Senior Scientist I to join our Bioassay Development team. This Senior Scientist I will support the development and evaluation of newly discovered oncology drugs and existing clinical candidates.
Responsibilities:
In this lab-based role, your major responsibilities will include the development of cell-based potency assays (bioassays) and ligand-binding potency assays, as well as performing potency testing and biological characterization in support of the development of therapeutic antibodies, antibody variants, and antibody drug conjugates (ADCs).
Qualifications
* Bachelors Degree in biology, cell/molecular biology, or a related field with typically 10 years of applicable industry experience, Masters Degree in biology, cell/molecular biology, or a related field with typically 5 years of applicable industry experience, or Ph.D. in biology, cell/molecular biology, or a related field with typically 2 years of applicable industry experience.
* Knowledge and proficiency with current binding potency assay approaches, such as ELISA, FACS, and/or other binding potency assay platforms (i.e. TR-FRET, Octet, AlphaLISA)
* Demonstrated proficiency with current bioassay methodologies, such as cytotoxicity assays, reporter assays, and/or flow cytometry.
* Experience performing cell-based assays and target binding potency assays to measure the biological activity of biologics drugs.
* Experience identifying performance issues with assays and independently developing creative solutions.
* Strong working knowledge and hands-on experience with mammalian cell culture (sterile cell culture technique, cell maintenance, counting, banking, transfection)
* Experience using PRISM, PLA, Softmax Pro, or similar data analysis software.
* Proven ability to work in a highly collaborative scientific environment.
* Strong verbal and written communication skills. Strong presentation skills.
* The ideal candidate will be hard-working, self-motivated, detail-oriented, highly organized, and able to learn and adapt quickly.
Significant Work Activities
N/A
Travel
No
Job Type
Experienced
Schedule
Full-time
Job Level Code
IC
Equal Employment Opportunity
At AbbVie, we value bringing together individuals from diverse backgrounds to develop new and innovative solutions for patients. As an equal opportunity employer we do not discriminate on the basis of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information gender identity or expression, sexual orientation, marital status, protected veteran status, or any other legally protected characteristic.
Chicago, IL
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia.
Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.